Call Us Toll Free: 1-800-388-9993

Dear DRIP Investors,


We have been helping people enroll in DRIPs since 1986. Many of our subscribers have written to express their thanks and describe the outcome of their DRIP investments. It has been a source of pride and our great pleasure to have assisted in your efforts to secure financial security.


However, after 35 years we have decided to stop fulfilling orders for enrollments after the March cycle. Moneypaper, via the directinvesting.com website, will continue to provide information about DRIPs and the enrollment process.


As always, good luck,

Vita Nelson

 

 

 

AstraZeneca PLC (AZN)

Available from the Temper Enrollment Service: No


Last Update On: 01/07/2021:

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab) and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. **Taken from Yahoo Finance**

Industry: Pharmaceutical R & D
Minimum Investment: $50.00
Maximum Investment: $10,000/investment
Shares to qualify: 1 or $250.00
Recent Price: 55.05
Investing Fee: $5+12¢/sh.
Fee for Dividends: 5% (to $2.50)+12¢/sh.

! = Company pays fees

Information is based on an annual survey and updated when company changes become available.

Click for Español

FOR MORE
INFORMATION

And a free copy of The Moneypaper's direct investing brochure, please enter your contact information below.

You will also be signed up to receive our monthly stock special.

You can unsubscribe at any time. We do not share your email with anyone.

By email, you get the Monthly “Stock Special,” where the service fee for enrollment in a great DRIP stock is reduced.

* Required Field.